Oral Relistor methylnaltrexone regulatory update

Valeant submitted an NDA to FDA for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. A subcutaneous formulation of the peripher...